Skip to content
OpenCapital
Get started

Cartesian Therapeutics, Inc. RNAC Q4 2024 Annual earnings

Reported March 20, 2025 · Before market open

Revenue$759.0KMiss by $241.0K
EPS-$0.59Beat by $0.19
Revenue estimate$1.0M
EPS estimate-$0.78

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$179.7K
EPS estimate-$0.83

Versus estimates

Revenue

Q1 2026$78.0KMiss by $141.8KQ4 2025$947.0KBeat by $796.7KQ3 2025$452.0KBeat by $351.8KQ2 2025$298.0KBeat by $120.4KQ1 2025$1.1MBeat by $412.5K
Q4 2024$759.0KMiss by $241.0K

Diluted EPS

Q1 2026-$1.46Miss by $0.62Q4 2025-$1.38Miss by $0.56Q3 2025-$1.38Miss by $0.57Q2 2025$0.50Beat by $1.26Q1 2025-$0.68Miss by $0.07
Q4 2024-$0.59Beat by $0.19

Ask the moment Cartesian Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Cartesian Therapeutics, Inc. report Q4 2024 earnings?
Cartesian Therapeutics, Inc. (RNAC) reported Q4 2024 earnings on March 20, 2025 before market open.
What were Cartesian Therapeutics, Inc.'s Q4 2024 revenue and EPS?
Cartesian Therapeutics, Inc. reported revenue of $759.0K and eps of $-0.59 for Q4 2024.
Did Cartesian Therapeutics, Inc. beat estimates in Q4 2024?
Revenue missed the consensus estimate of $1.0M by $241.0K. EPS beat the consensus estimate of $-0.78 by $0.19.
Where can I find Cartesian Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0001453687-25-000060) directly on SEC EDGAR. The filing index links above go to sec.gov.